IHM
Iguana Healthcare Management Portfolio holdings
AUM
$133M
This Quarter Return
-10.81%
1 Year Return
+45.66%
3 Year Return
+127.07%
5 Year Return
–
10 Year Return
–
AUM
$214M
AUM Growth
+$214M
(-18%)
Cap. Flow
-$9.15M
Cap. Flow
% of AUM
-4.27%
Top 10 Holdings %
Top 10 Hldgs %
48.31%
Holding
91
New
24
Increased
15
Reduced
16
Closed
24
Top Buys
| 1 |
MDVN
MEDIVATION, INC.
MDVN
|
$9.89M |
| 2 |
Zimmer Biomet
ZBH
|
$9.06M |
| 3 |
HCA Healthcare
HCA
|
$7.81M |
| 4 |
Medtronic
MDT
|
$7.5M |
| 5 |
Pfizer
PFE
|
$5.93M |
Top Sells
| 1 |
Viatris
VTRS
|
$12.2M |
| 2 |
Teva Pharmaceuticals
TEVA
|
$9.85M |
| 3 |
Amgen
AMGN
|
$9.75M |
| 4 |
AET
Aetna Inc
AET
|
$5.41M |
| 5 |
ESRX
Express Scripts Holding Company
ESRX
|
$5.25M |
Sector Composition
| 1 | Healthcare | 86.48% |
| 2 | Industrials | 0.5% |
| 3 | Consumer Staples | 0% |
| 4 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
CELG
1
DELISTED
Celgene Corp
CELG
| $17.5M | 6.42% | 175,000 -25,000 | -13% | -$2.5M |
|
2
Cigna
CI
$80.3B
| $13.7M | 5.03% | 100,000 -35,000 | -26% | -$4.8M |
|
|
MDVN
3
DELISTED
MEDIVATION, INC.
MDVN
| $12.2M | 4.46% | 265,000 +215,000 | +430% | +$9.89M |
|
4
Baxter International
BAX
$12.7B
| $11.9M | 4.37% | 290,000 -35,000 | -11% | -$1.44M |
|
|
5
Zimmer Biomet
ZBH
$21B
| $9.06M | 3.32% | +85,000 | New | +$9.06M |
|
6
Merck
MRK
$210B
| $7.94M | 2.91% | 150,000 +50,000 | +50% | +$2.65M |
|
7
Biogen
BIIB
$19.4B
| $7.81M | 2.86% | 30,000 +10,000 | +50% | +$2.6M |
|
8
Gilead Sciences
GILD
$140B
| $7.81M | 2.86% | 85,000 -5,000 | -6% | -$459K |
|
|
9
HCA Healthcare
HCA
$94.5B
| $7.81M | 2.86% | +100,000 | New | +$7.81M |
|
10
Ultragenyx Pharmaceutical
RARE
$2.89B
| $7.6M | 2.78% | 120,000 +5,000 | +4% | +$317K |
|
|
11
Medtronic
MDT
$119B
| $7.5M | 2.75% | +100,000 | New | +$7.5M |
|
|
12
Pfizer
PFE
$141B
| $5.93M | 2.17% | +200,000 | New | +$5.93M |
|
13
Eli Lilly
LLY
$657B
| $5.4M | 1.98% | +75,000 | New | +$5.4M |
|
|
14
Amgen
AMGN
$155B
| $5.25M | 1.92% | 35,000 -65,000 | -65% | -$9.75M |
|
15
Tenet Healthcare
THC
$16.3B
| $5.06M | 1.86% | 175,000 +100,000 | +133% | +$2.89M |
|
|
NUVA
16
DELISTED
NuVasive, Inc.
NUVA
| $4.87M | 1.78% | 100,000 +50,000 | +100% | +$2.43M |
|
|
OMED
17
DELISTED
OncoMed Pharmaceuticals, Inc.
OMED
| $4.72M | 1.73% | 467,025 +67,025 | +17% | +$678K |
|
18
Supernus Pharmaceuticals
SUPN
$2.53B
| $4.19M | 1.54% | 275,000 +125,000 | +83% | +$1.91M |
|
|
GBT
19
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $3.97M | 1.45% | 250,000 +140,000 | +127% | +$2.22M |
|
20
Alnylam Pharmaceuticals
ALNY
$58.5B
| $3.77M | 1.38% | 60,000 +35,000 | +140% | +$2.2M |
|
21
Boston Scientific
BSX
$156B
| $3.76M | 1.38% | +200,000 | New | +$3.76M |
|
|
MDRX
22
DELISTED
Veradigm Inc. Common Stock
MDRX
| $3.3M | 1.21% | 250,000 -25,000 | -9% | -$330K |
|
|
ADMS
23
DELISTED
Adamas Pharmaceuticals, Inc.
ADMS
| $2.89M | 1.06% | 200,000 +140,000 | +233% | +$2.02M |
|
24
Regeneron Pharmaceuticals
REGN
$61.5B
| $2.7M | 0.99% | +7,500 | New | +$2.7M |
|
25
Dynavax Technologies
DVAX
$1.19B
| $2.69M | 0.99% | +140,000 | New | +$2.69M |
|